Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081981 | 1.00 | CRHR1 (0.35) | CRHR1TACR2IDO1SLC6A2SLC6A4 | |
| SCHEMBL6083147 | 0.82 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL6083159 | 0.82 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL6082492 | 0.81 | CRHR1 (0.42) | CRHR1TACR2 | |
| SCHEMBL6082485 | 0.81 | CRHR1 (0.42) | CRHR1TACR2 | |
| SCHEMBL6082233 | 0.79 | TP53 (0.37) | CRHR1TACR2 | |
| SCHEMBL6082225 | 0.79 | TP53 (0.37) | CRHR1TACR2 | |
| SCHEMBL6817680 | 0.76 | TLR7 (0.34) | — | |
| SCHEMBL6082269 | 0.75 | CRHR1 (0.38) | CRHR1 | |
| SCHEMBL6082274 | 0.75 | CRHR1 (0.38) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | CRHR1 1/4885TACR2 189/4885IDO1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.